DNA损伤修复通路基因多态性与铂类药物治疗非小细胞肺癌敏感性及预后关系的研究进展

doi:10.13481/j.1671-587x.20180434

摘要/Abstract

摘要： 铂类药物是肺癌治疗中应用最广泛的首选化疗药物之一，其通过损伤DNA而诱导肿瘤细胞凋亡。DNA损伤修复功能的变化是引发肿瘤患者对铂类药物耐药的重要分子学基础，DNA损伤修复通路相关基因的单核苷酸多态性（SNPs）与DNA修复能力的改变有关联，核苷酸切除修复通路（NER通路）及碱基切除修复通路（BER通路）相关基因的SNPs对修复铂类药物引起的DNA损伤起重要作用。本文作者对近几年关于NER通路及BER通路相关基因的多态性与晚期非小细胞肺癌（NSCLC）患者应用铂类药物为基础的化疗方案治疗的敏感性及预后之间关系进行综述。

关键词: 非小细胞肺癌, 碱基切除修复, 铂类药物, 基因多态性, DNA损伤修复, 核苷酸切除修复

中图分类号:

R734.2

董洁, 王旭, 崔久嵬. DNA损伤修复通路基因多态性与铂类药物治疗非小细胞肺癌敏感性及预后关系的研究进展[J]. 吉林大学学报(医学版), 2018, 44(04): 869-874.

参考文献

[1] Fennell DA,Summers Y,Cadranel J,et al. Cisplatin in the modern era:The backbone of first-line chemotherapy for non-small cell lung cancer[J]. Cancer Treat Rev,2016,44:42-50.
[2] Santarpia M,Rolfo C,Peters GJ,et al.On the pharmacogenetics of non-small cell lung cancer treatment[J].Expert Opin Drug Metab Toxicol,2016,12(3):307-317.
[3] Yin JY,Li X,Zhou HH,et al.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC:toward precision medicine[J].Pharmacogenomics,2016,17(12):1365-1378.
[4] Yamaguchi M,Sugio K.Current status of induction treatment for N2-Stage Ⅲ non-small cell lung cancer[J].Gen Thorac Cardiovasc Surg,2014,62(11):651-659.
[5] Sakthivel KM,Hariharan S.Regulatory players of DNA damage repair mechanisms:role in cancer chemoresistance[J].Biomed Pharmacother,2017,93:1238-1245.
[6] Sarries C,Haura EB,Roig B,et al.Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer[J].Pharmacogenomics,2002,3(6):763-780.
[7] Chen X,Sun H,Ren S,et al.Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients[J].Clin Transl Oncol,2012,14(3):207-213.
[8] Melton DW,Ketchen AM,Nunez F,et al.Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination[J].J Cell Sci,1998,111(Pt 3):395-404.
[9] Park SY,Hong YC,Kim JH,et al.Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients[J].Med Oncol,2006,23(4):489-498.
[10] Lv H,Han T,Shi X,et al.Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer[J].Med Oncol,2014,31(8):86.
[11] Yu SN,Liu GF,Li XF,et al.Evaluation of prediction of polymorphisms of DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer:A network meta-analysis[J].J Cell Biochem,2017,118(12):4782-4791.
[12] Xu TP,Shen H,Liu LX,et al.Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy:a pooled analysis based on 39 reports[J].Gene,2013,526(2):265-274.
[13] 张增利,朱晓良,陈婷,等.DNA修复基因ERCC1多态性与晚期肺腺癌患者接受含铂方案化疗疗效的关系[J].江苏医药,2015,41(21):2524-2526.
[14] Zhao X,Zhang Z,Yuan Y,et al.Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients[J].Tumour Biol,2014,35(8):8335-8341.
[15] Huang D,Zhou Y.Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy:A meta-analysis based on 44 studies[J].Biomed Rep,2014,2(4):452-462.
[16] Chen P,Wiencke J,Aldape K,et al.Association of an ERCC1 polymorphism with adult-onset glioma[J].Cancer Epidemiol Biomarkers Prev,2000,9(8):843-847.
[17] Li F,Sun X,Sun N,et al.Association Between Polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer[J].Am J Clin Oncol Cancer,2010,33(5):489-494.
[18] Tan LM,Qiu CF,Zhu T,et al.Genetic polymorphisms and platinum-based chemotherapy treatment outcomes in patients with non-small cell lung cancer:A genetic epidemiology study based Meta-analysis[J].Sci Rep,2017(1):5593.
[19] KimCurran V,Zhou C,Schmid-Bindert G,et al.Lack of correlation between ERCC1(C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer[J].Adv Med Sci Poland,2011,56(1):30-38.
[20] Liu H,Rudolf J,Johnson KA,et al.Structure of the DNA repair helicase XPD[J].Cell,2008,133(5):801-812.
[21] Long XD,Ma Y,Zhou YF,et al.XPD codon 312 and 751 polymorphisms,and AFB1 exposure,and hepatocellular carcinoma risk[J].BMC Cancer,2009,17(9):400.
[22] Kiyohara C,Yoshimasu K.Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk:a meta-analysis[J].Int J Med Sci,2007,4(2):59-71.
[23] 李代蓉,杨燕青,黄新华,等.ERCC2多态性与肺癌铂类化疗敏感性的关系[J].中国现代医学杂志,2011,21(17):2004-2007,2012.
[24] Qin Q,Zhang C,Yang X,et al.Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients:a meta-analysis of 24 studies[J].PLoS One,2013,8(11):e79864.
[25] Lawania S,Singh N,Behera D,et al.Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy[J].Future Oncol,2017,13(29):2645-2665.
[26] Zhang G,Guan Y,Zhao Y,et al.ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway[J].Chem Biol Interact,2017,263:55-65.
[27] 陈敏,胡志坚.DNA修复基因与肝癌关系的研究进展[J].现代预防医学,2009,(23):4549-4550,4553.
[28] Wang S,Wang J,Bai Y,et al.The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients[J].Cancer Med,2016,5(9):2332-2342.
[29] Li DJ,Xiao D.Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy:a meta-analysis based on the PRISMA statement[J].BMC Cancer,2017,17(1):501.
[30] Bu L,Zhang LB,Mao X,et al.GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer[J].Genet Mol Res,2016,15(2).doi:10.4238/gmr.15027611
[31] Liu HF,Liu JS,Deng JH,et al.Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy,and their effect on clinical and pathological characteristics[J].Genet Mol Res,2016,15(4).doi:10.4238/gmr.15049084.
[32] 许崇安,李嵚,王小杰,等.ERCC1和XRCC1多态性与进展期非小细胞肺癌对铂类化疗的敏感性[J].实用肿瘤杂志,2012,27(3):245-250.
[33] 付婷,秦立强,潘旭东,等.XRCC1基因多态性与晚期非小细胞肺癌铂类化疗敏感性关系的Meta分析[J].江苏医药,2015,41(12):1401-1403.
[34] Yuan P,Liu L,Wu C,et al.No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy[J].Cancer Biol Ther,2010,10(9):854-859.
[35] 许崇安,王小杰,张晔,等.XRCC1和XRCC3单核苷酸多态性与晚期非小细胞肺癌铂类药物化疗疗效的相关性[J].中国肺癌杂志,2011,14(12):912-917.
[36] Su D,Ma S,Liu P,et al.Genetic polymorphisms and treatment response in advanced non-small cell lung cancer[J].Lung Cancer,2007,56(2):281-288.
[37] Wei Q,Frazier ML,Levin B.DNA repair:a double-edged sword[J].J Natl Cancer Inst,2000,92(6):440-441.
[38] 赵万,胡铃敏,王铖,等.XRCC1、PARP1和APE1多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系[J].南京医科大学学报:自然科学版,2011,31(7):1021-1026.
[39] Zhao W,Hu L,Xu J,et al.Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer[J].Cancer Chemother Pharmacol,2013,71(5):1287-1295.
[40] Shiraishi K,Kohno T,Tanai C,et al.Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer[J].J Clin Oncol,2010,28(33):4945-4952.
[41] Nogueira A,Assis J,Faustino I,et al.Base excision repair pathway:PARP1 genotypes as modulators of therapy response in cervical cancer patients[J].Biomarkers,2017,22(1):70-76.
[42] Li H,Hao X,Zhang W,et al.The hOGG1 Ser326Cys polymorphism and lung cancer risk:a meta-analysis[J].Cancer Epidemiol Biomarkers Prev,2008,17(7):1739-1745.
[43] 杜国波,马代远,谭榜宪,等.hOGG1基因多态性与肺癌化疗疗效及预后关系的研究[J].现代肿瘤医学,2014,22(3):552-555.
[44] Su Y,Zhang H,Xu F,et al.DNA repair gene polymorphisms in relation to non-small cell lung cancer survival[J].Cell Physiol Biochem,2015,36(4):1419-1429.
[45] Peng Y,Li Z,Zhang S,et al.Association of DNA base excision repair genes (OGG1,APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients[J].Int J Cancer,2014,135(11):2687-2696.
[46] Singh A,Singh N,Behera D,et al.Genetic investigation of polymorphic OGG1 and MUTYH genes towards increased susceptibility in lung adenocarcinoma and its impact on overall survival of lung cancer patients yreated with platinum based chemotherapy[J].Pathol Oncol Res,2017,5:1-14.
[47] Lu AL,Li X,Gu Y,et al.Repair of oxidative DNA damage:mechanisms and functions[J].Cell Biochem Biophys,2001,35(2):141-170.
[48] Osawa K,Nakarai C,Uchino K,et al.XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients[J].Int J Mol Sci,2012,13(12):16658-16667.
[49] 潘萌,王乐,李旭,等.原发性肝癌合并肺腺癌肝转移1 例报告[J].临床肝胆病杂志, 2017,33(4):732-734.
[50] 颜欣,宋鑫月,董洪静,等.急性广泛门静脉系统血栓合并肺栓塞1 例报告[J].临床肝胆病杂志, 2018, 34(4):845-847.
[51] 刘以俊,李涛.《2016年国际肝移植学会实践指南:肝肺综合征与门脉性肺动脉高压的诊断与管理》摘译[J].临床肝胆病杂志,2016, 32(10):1838-1842.